In the last trading session, 1,570,632 AzurRx BioPharma, Inc. (NASDAQ:AZRX) shares changed hands as the company’s beta touched 1.52. With the company’s per share price at $0.8 changed hands at -$0.04 or -0.04% during last session, the market valuation stood at $63.13 Million. AZRX’s last price was a discount, traded about -228.75% off its 52-week high of $2.63. The share price had its 52-week low at $0.65, which suggests the last value was 18.75% up since then. When we look at AzurRx BioPharma, Inc.’s average trading volume, we note the 10-day average is 1.02 Million shares, with the 3-month average coming to 2.59 Million.
Analysts gave the AzurRx BioPharma, Inc. (AZRX) stock a consensus recommendation rating of Overweight, calculated at a mean rating of 2.2. If we narrow down to specifics, the data shows that none out of 4 analysts rate the stock as a Sell, with a further none assigning it an Overweight rating. Of the remaining, 1 recommended AZRX as a Hold, 3 felt it is a Buy and none rated the stock as Underweight. AzurRx BioPharma, Inc.’s EPS for the current quarter is expected to be -$0.06.
AzurRx BioPharma, Inc. (NASDAQ:AZRX) trade information
Although AZRX has turned red as seen at the end of in last trading. With action -3.81%, the performance over the past five days has been red. The jump to weekly highs of $0.885 on Tuesday, Jun 15 added 9.22% to the stock’s daily price. The company’s shares are showing year-to-date downside of -0.17%, with the 5-day performance at -0.07% in the red. However, in the 30-day time frame, AzurRx BioPharma, Inc. (NASDAQ:AZRX) is -0.1% down. Looking at the short shares, we see there were 2.39 Million shares sold at short interest cover period of 0.92 days.
The consensus price target for the stock as assigned by Wall Street analysts is $3.5, meaning bulls need an upside of 337.5% from its current market value. According to analyst projections, AZRX’s forecast low is $2.5 with $5 as the target high. To hit the forecast high, the stock’s price needs a +525% upsurge from its current level, while the stock would need to tank 212.5% for it to hit the projected low.
AzurRx BioPharma, Inc. (AZRX) estimates and forecasts
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -19%. The 2021 estimates are for AzurRx BioPharma, Inc. earnings to decrease by -116.8%, but the outlook for the next 5-year period is at 0% per year.
AzurRx BioPharma, Inc. (NASDAQ:AZRX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.97% of AzurRx BioPharma, Inc. shares while 4.09% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 4.13%. There are 33 institutions holding the AzurRx BioPharma, Inc. stock share, with Vanguard Group, Inc. (The) the top institutional holder. As of Mar 30, 2021, the company held 1.37% of the shares, roughly 1.08 Million AZRX shares worth $1.44 Million.
Bank Of New York Mellon Corporation holds the second largest percentage of outstanding shares, with 0.83% or 652.03 Thousand shares worth $873.71 Thousand as of Mar 30, 2021.
Among Mutual Funds, the top two as of Mar 30, 2021 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. With 627917 shares estimated at $841.41 Thousand under it, the former controlled 0.8% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.45% of the shares, roughly 355.12 Thousand shares worth around $475.86 Thousand.